Development of an intravenous formulation of SU010382 (Prodrug of SU5416, an anti-angiogenesis agent)

PDA Journal of Pharmaceutical Science and Technology

Volumn 62, Issue 3, 2008, Pages 200-210

  Sistla, Anand ^a   Kertelj, Adriana ^b   Shenoy, Narmada ^c  

^a PFIZER INC   (United States)

^b Nerviano Medical Sciences   (Italy)

^c AraVasc Inc   (United States)

Author keywords

Intravenous; Lyophilized; Prodrug; SU010382; SU5416; Sulfobutyl ether cyclodextrin

Indexed keywords

ANGIOGENESIS INHIBITOR; BETA CYCLODEXTRIN SULFOBUTYL ETHER; MACROGOL DERIVATIVE; MANNITOL; MESYLIC ACID; POLYSORBATE 80; SEMAXANIB; SU 010382; UNCLASSIFIED DRUG; BETA CYCLODEXTRIN DERIVATIVE; INDOLE DERIVATIVE; MANNICH BASE; PRODRUG; PYRROLE DERIVATIVE; SBE4 BETA CYCLODEXTRIN; SBE4-BETA-CYCLODEXTRIN; SOLVENT; SURFACTANT;

ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG DESIGN; DRUG FORMULATION; DRUG MANUFACTURE; DRUG STABILITY; DRUG STORAGE; DRUG STRUCTURE; FREEZE DRYING; PH; PHYSICAL CHEMISTRY; CHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; SOLUBILITY; TEMPERATURE;

ANGIOGENESIS INHIBITORS; BETA-CYCLODEXTRINS; DRUG STABILITY; DRUG STORAGE; FREEZE DRYING; HYDROGEN-ION CONCENTRATION; INDOLES; INJECTIONS, INTRAVENOUS; MANNICH BASES; PRODRUGS; PYRROLES; SOLUBILITY; SOLVENTS; SURFACE-ACTIVE AGENTS; TEMPERATURE;

EID: 50949120901     PISSN: 10797440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Fong, T. A.; Shawver, L. K.; Sun, L.; Tang, C.; App, H.; Powell, T. J.; Kim, Y. H.; Schreck, R.; Wang, X.; Risau, W.; Ullrich, A.; Hirth, K. P.; McMahon, G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Research 1999, 59, 99-106.
2. Shaheen, R. M.; Davis, D. W.; Liu, W.; Zebrowski, B. K.; Wilson, M. R.; Bucana, C. D.; McConkey, D. J.; McMahon, G.; Ellis, L. M. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Research 1999, 59, 5412-5416.
3. Mendel, D. B.; Laird, A. D.; Smolich, B. D.; Blake, R. A.; Liang, C.; Hannah, A. L.; Shaheen, R. M.; Ellis, L. M.; Weitman, S.; Shawver, L. K.; Cherrington, J. M. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anti-Cancer Drug Design 2000, 15, 29-41.
4. Shenoy, N.; Wagner, G. S. Formulations for Hydrophobic Pharmaceutical Agents. U.S. Patent 6,248,771, 2001.
5. Sistla, A.; Shenoy, N. Reversible Z-E isomerism and pharmaceutical implications. Drug Dev. Ind. Pharm. 2005, 31, 1001-1007.
6. Moon, M. W.; Morozowich, W.; Gao, P.; Tang, P. C. Mannich Base Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone Derivatives. U.S. Patent 6,710,067, 2004.
7. Bundgaard, H.; Johansen, M. Prodrugs as drug delivery systems. IV. N-Mannich bases as potential novel prodrugs for amides, ureides, amines, and other NH-acidic compounds. J. Pharm. Sci. 1980, 69, 44-46.
8. Koch, S. A. M.; Sloan, K. B. N-Mannich base derivatives of 5-fluorocytosine: a prodrug approach to improve topical delivery. Int. J. Pharm. 1987, 35, 243-252.
9. Doshi, A.; Deshpande, S. G. Prodrugs of ibuprofen. II. Kinetics of decomposition of N-Mannich base prodrugs. Indian Journal of Pharmaceutical Sciences 2002, 64, 445-448.
10. Cogan, P. S.; Fowler, C. R.; Post, G. C.; Koch, T. H. Doxsaliform: A novel N-Mannich base prodrug of a doxorubicin formaldehyde conjugate. Letters in Drug Design & Discovery 2004, 1, 247-255.
11. Loftsson, T.; Brewster, M. E. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci. 1996, 85, 1017-1025.
12. Li, P.; Tabibi, S.; Esmail, Y.; Yalkowsky, S. H. Combined effect of complexation and pH on solubilization. J. Pharm. Sci. 1998, 87, 1535-1537.
13. Zia, V.; Rajewski, R. A.; Stella, V. J. Effect of cyclodextrin charge on complexation of neutral and charged substrates: comparison of sulfobutyl ether-β-cyclodextrin to hydroxypropyl β-cyclodextrin. Pharm. Res. 2001, 18, 667-673.
14. Higuchi, T.; Connors, K. A. Phase Solubility Techniques. In Advances in Analytical Chemistry and Instrumentation; Reilly, C. N., Ed.; Wiley-Interscience: New York, 1965; p 117-212.
15. Huang, C. Y. Determination of binding stoichiometry by the continuous variation method: the Job plot. Methods in Enzymology 1982, 87, 509-525.
16. Mueller, B. W.; Brauns, U. Solubilization of drugs by modified β-cyclodextrins. Int. J. Pharm. 1985, 26, 77-88.
17. Mueller, B. W.; Brauns, U. Hydroxypropyl-β-cyclodextrin derivatives: Influence of average degree of substitution on complexing ability and surface activity. J. Pharm. Sci. 1986, 75, 571-572.
18. Thompson, D. O. Cyclodextrins - enabling excipients: Their present and future use in pharmaceuticals. Critical Reviews in Therapeutic Drug Carrier Systems 1997, 14, 1-104.
19. Okimoto, K.; Rajewski, R. A.; Uekama, K.; Jona, J. A.; Stella, V. J. The interaction of charged and uncharged drugs with neutral (HP-β-CD) and anionically charged (SBE7-β-CD) β-cyclodextrins. Pharm. Res. 1996, 13, 256-264.
20. Waterman, K. C.; Adami, R. C.; Alsante, K. M.; Antipas, A. S.; Arenson, D. R.; Carrier, R.; Hong, J.; Landis, M. S.; Lombardo, F.; Shah, J. C.; Shalaev, E.; Smith, S. W.; Wang, H. Hydrolysis in pharmaceutical formulations. Pharmaceutical Development and Technology 2002, 7, 113-146.
21. Aramwit, P.; Kerdcharoen, T.; Qi, H. In vitro plasma compatibility study of a nanosuspension formulation. PDA J. Pharm. Sci. Technol. 2006, 60 (4), 211-217.